ImmunityBio (IBRX)
(Real Time Quote from BATS)
$6.23 USD
+0.08 (1.30%)
Updated Jun 5, 2024 10:04 AM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
IBRX 6.23 +0.08(1.30%)
Will IBRX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for IBRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IBRX
Here's Why ImmunityBio (IBRX) Is a Great 'Buy the Bottom' Stock Now
ImmunityBio (IBRX)'s Technical Outlook is Bright After Key Golden Cross
IBRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Qiagen (QGEN) Q3 Earnings and Revenues Surpass Estimates
Should IQ Chaikin U.S. Small Cap ETF (CSML) Be on Your Investing Radar?
FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing
Other News for IBRX
ImmunityBio, LadRx end licensing deal for cancer drug
These 3 Interesting Stocks Are Seeing Heavy Short Interest In June 2024
Largest borrow rate increases among liquid names
Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo
Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast